Molecular basis for binding and subtype selectivity of 1,4-benzodiazepine antagonist ligands of the cholecystokinin receptor.
about
Cholecystokinin-induced satiety, a key gut servomechanism that is affected by the membrane microenvironment of this receptorA type 1 cholecystokinin receptor mutant that mimics the dysfunction observed for wild type receptor in a high cholesterol environment.Development of a highly selective allosteric antagonist radioligand for the type 1 cholecystokinin receptor and elucidation of its molecular basis of bindingElimination of a cholecystokinin receptor agonist 'trigger' in an effort to develop positive allosteric modulators without intrinsic agonist activity.Impact of ursodeoxycholic acid on a CCK1R cholesterol-binding site may contribute to its positive effects in digestive function.Sensitivity of cholecystokinin receptors to membrane cholesterol content.Molecular Mechanism of Action of Triazolobenzodiazepinone Agonists of the Type 1 Cholecystokinin Receptor. Possible Cooperativity across the Receptor Homodimeric Complex.Direct demonstration of unique mode of natural peptide binding to the type 2 cholecystokinin receptor using photoaffinity labeling.Molecular basis for benzodiazepine agonist action at the type 1 cholecystokinin receptor.Metabolic Actions of the Type 1 Cholecystokinin Receptor: Its Potential as a Therapeutic Target.Beneficial effects of β-sitosterol on type 1 cholecystokinin receptor dysfunction induced by elevated membrane cholesterol.Structural studies on radiopharmaceutical DOTA-minigastrin analogue (CP04) complexes and their interaction with CCK2 receptor.Gastrin receptor pharmacology.
P2860
Q33838127-82809314-8A6B-4546-8FCB-B2B4663E4205Q34073933-7F169C89-5164-496B-A2F3-B5B3008A5DDCQ34785475-8EB278C3-85DD-489F-A1F0-BADE75CA1C74Q35533535-BCB0E583-FEE0-4D39-A767-5CE29254D705Q36017828-68228B7A-C0D1-42E6-BFEE-A5EFEF875122Q36329391-D5B917C3-8093-4BD9-9C4A-63B5D05FD002Q36683781-0DF7D6D2-533F-441C-AA69-E11140B24E50Q37084882-46920D58-9AD1-436C-B8A7-B55ED8859D1FQ37175130-A66777D0-ADB7-4218-B716-5B75E51C4CD2Q38828407-CB031E0E-1897-4AA3-A018-8C7353F73C62Q39888037-BD31FC05-0683-4D2A-968C-0DA5DB454FB6Q52319422-A1E95581-284E-4284-AC22-6B9F2FC4D98AQ54483223-159DAF3A-CE45-40E8-BF28-32E991C93AEA
P2860
Molecular basis for binding and subtype selectivity of 1,4-benzodiazepine antagonist ligands of the cholecystokinin receptor.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Molecular basis for binding an ...... the cholecystokinin receptor.
@ast
Molecular basis for binding an ...... the cholecystokinin receptor.
@en
type
label
Molecular basis for binding an ...... the cholecystokinin receptor.
@ast
Molecular basis for binding an ...... the cholecystokinin receptor.
@en
prefLabel
Molecular basis for binding an ...... the cholecystokinin receptor.
@ast
Molecular basis for binding an ...... the cholecystokinin receptor.
@en
P2093
P2860
P356
P1476
Molecular basis for binding an ...... the cholecystokinin receptor.
@en
P2093
Alicja M Ball
Andrew Orry
Erin E Cawston
Eyup Akgün
Kaleeckal G Harikumar
Laurence J Miller
Maoqing Dong
Mary Lou Augustine
Patrick M Sexton
Philip S Portoghese
P2860
P304
18618-18635
P356
10.1074/JBC.M111.335646
P407
P577
2012-03-30T00:00:00Z